CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Algorae Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Algorae Pharmaceuticals Ltd
Level 23,, Rialto South Tower,,
525 Collins Street,
Phone: +61 300288664p:+61 300288664 MELBOURNE, VIC  3000  Australia Ticker: 1AI1AI
Business Summary
Algorae Pharmaceuticals Limited is an Australia-based artificial-intelligence (AI) enabled pharmaceutical development company. The Company’s proprietary AI platform, Algorae Operating System (AlgoraeOS), is an AI platform that leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. Its other drug candidates include AI-116, AI-168, NTCELL. AI-116 is a combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease. AI-168 is a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient, which is conceptualized to be a potential treatment for cardiovascular disease, including hypertension. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20256/30/2025Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board David R.Hainsworth 1/5/2023 10/30/2022
Chief Financial Officer DayaUka
Chief Scientific Officer James A.Mckenna 6/9/2023 6/9/2023
5 additional Officers and Directors records available in full report.

Business Names
Business Name
1AI
LCT
Living Cell Technologies Ltd.
LVCLY

General Information
Number of Employees: 48 (As of 6/30/2008)
Outstanding Shares: 1,687,394,731 (As of 6/30/2025)
Shareholders: 2,638
Stock Exchange: ASX
Fax Number: +61 417935552


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 1, 2025